9th Report - The impact of Brexit on the pharmaceutical sector
- HC No.
- HC 382
- Published
- 17 May 2018
- Items
- 0
- Response
- Response document linked Read government response ↗
Select Committee · Business, Innovation, Science and Trade Committee
Brexit and the implications for UK business: Pharmaceuticals inquiry
Status: Closed
Opened: 20 Sep 2017
Closed: 14 Sep 2017
1 report
Inquiry scope
This is the pharmaceuticals strand of the Committee's Brexit and the implications for UK business inquiry . The Committee aims to establish how the interests of different sectors should best be pursued both in the negotiating process and post-Brexit and attempts to examine a range of issues relating to market access, non-tariff barriers, regulation, skills, R&D, trade opportunities and transitional arrangements. Terms of reference: Brexit and the implications for UK businessReports
Oral evidence sessions
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Date | Session and witnesses | Source |
|---|---|---|
| 5 Dec 2017 | No witnesses recorded | View ↗ |